Mineralocorticoid receptor antagonists, commonly called MRAs, are drugs that block the action of aldosterone, a hormone your body makes to regulate sodium, potassium, and water balance. By sitting in the receptor that aldosterone normally activates, these drugs prevent the hormone from triggering salt and water retention, and they also counteract the tissue-damaging inflammation and scarring that aldosterone drives in the heart, kidneys, and blood vessels. That dual role, addressing both fluid overload and organ damage, explains why MRAs have become a cornerstone treatment for conditions ranging from heart failure to resistant high blood pressure to chronic kidney disease.
How MRAs Work at the Cellular Level
Aldosterone is produced in the adrenal glands and travels through the bloodstream to tissues that express the mineralocorticoid receptor (MR). In the kidneys, the receptor sits primarily in cells lining the collecting duct, one of the final stretches of the tiny tubules that filter your blood. When aldosterone binds the receptor there, it switches on a cascade that ultimately increases the number and activity of sodium channels on the cell surface. More sodium gets pulled back into the body, water follows, and potassium gets excreted in exchange. The net result is higher blood volume and higher blood pressure.1Bioscientifica Journals (Journal of Endocrinology). 30 YEARS OF THE MINERALOCORTICOID RECETOR: Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron – Section: MR signaling in principal cells of the collecting duct
MRAs compete with aldosterone for that same receptor. When the drug occupies the binding pocket, aldosterone cannot get in, and the downstream signal to retain sodium never fires. Sodium and water leave the body in urine, potassium is spared, and blood pressure drops. But the story does not end in the kidneys. Mineralocorticoid receptors also exist in blood vessel walls, heart muscle, the brain, and immune cells, where inappropriate activation contributes to inflammation, stiffness, and scarring.2PubMed Central. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature Blocking those receptors throughout the body accounts for much of the benefit MRAs provide beyond simple fluid control.
Steroidal Versus Non-Steroidal MRAs
The first generation of MRAs are steroidal compounds, meaning their chemical structure resembles that of steroid hormones. Spironolactone, introduced in the late 1950s, is the oldest and most widely prescribed. Eplerenone arrived decades later and is more selective for the mineralocorticoid receptor, which matters because spironolactone also binds androgen and progesterone receptors, producing side effects like breast tenderness in men and menstrual irregularities in women.3PubMed. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone Canrenone, a metabolite of spironolactone available primarily in parts of Europe and South America, occupies a middle ground.
The newest class, non-steroidal MRAs, has a fundamentally different chemical backbone. Finerenone is the first to reach widespread clinical use. Compared with spironolactone, which concentrates heavily in the kidneys, finerenone distributes more evenly between the heart and the kidneys. Its binding mode and the downstream genes it switches on also differ, with pronounced anti-fibrotic effects in preclinical models.4PubMed Central. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine These differences are not just pharmacological curiosities; they translate into distinct clinical profiles, with finerenone causing less hyperkalemia in some settings and showing particular benefit in diabetic kidney disease.
Heart Failure with Reduced Pumping Strength
Heart failure with a reduced ejection fraction (the heart pumps out a smaller fraction of blood with each beat) was the condition that first proved MRAs could save lives. The landmark trial of spironolactone in severe heart failure was stopped early because patients on the drug had a roughly 30% lower risk of death compared with placebo.5JHLT Open. The state of the art in medical therapies for pediatric heart failure – Section: Inhibitors of the renin-angiotensin-aldosterone system Eplerenone later showed similar mortality benefits after heart attacks complicated by weakened heart function.
A network meta-analysis of 32 randomized trials involving over 15,000 patients compared the available MRAs head-to-head. Eplerenone ranked slightly better than spironolactone for reducing overall death, while spironolactone was superior at preventing hospital admissions for worsening heart failure. Canrenone, though studied in fewer and smaller trials, ranked first for both overall mortality and heart-failure hospitalization.6PubMed. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials A separate Bayesian analysis confirmed canrenone’s strong showing for hospitalization outcomes and found spironolactone and finerenone also delivered meaningful reductions in cardiovascular death.7European Heart Journal. Comparative effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a comprehensive Bayesian network meta-analysis with intervention ranking Practically speaking, guidelines recommend an MRA for most patients with this form of heart failure, and clinicians choose among them based on side-effect profile, kidney function, and drug availability.
Heart Failure with Preserved Pumping Strength
When the heart contracts normally but fills stiffly, the condition is called heart failure with preserved ejection fraction. This has been one of the harder forms of heart failure to treat, and MRAs have had mixed results here. A meta-analysis of trials found that MRAs improved echocardiographic markers of how well the heart relaxes and lowered blood pressure, but those improvements did not consistently translate into better exercise capacity or quality of life for patients. Hyperkalemia and worsening kidney function were common side effects in the MRA groups.8PubMed Central. Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Finerenone may be changing this picture. In patients who have heart failure with preserved or mildly reduced ejection fraction, finerenone improved outcomes related to worsening heart failure and cardiovascular death, expanding on benefits previously seen in diabetic kidney disease populations.9PubMed. Mineralocorticoid Receptor Antagonists in Heart Failure: An Update The distinction between the older steroidal agents and the newer non-steroidal agents may matter most in this particular subset of heart failure, where organ-level fibrosis rather than simple fluid overload appears to drive much of the problem.
Resistant Hypertension
Resistant hypertension, where blood pressure remains above target despite three or more drugs at adequate doses, affects a substantial minority of people treated for high blood pressure. Spironolactone has become the go-to add-on for these patients. In one study of subjects with resistant hypertension, low-dose spironolactone lowered blood pressure by an average of about 25/12 mmHg at six months, an effect that was additive on top of the drugs patients were already taking and was similar regardless of whether primary aldosteronism was present.10American Journal of Hypertension. Efficacy of low-dose spironolactone in subjects with resistant hypertension
The PATHWAY-2 trial, a rigorous crossover study, confirmed that spironolactone reduced blood pressure substantially more than conventional alternatives in people with resistant hypertension. The researchers concluded that this form of hypertension is commonly a salt-retaining state, likely driven by inappropriate aldosterone production, and that blocking the mineralocorticoid receptor directly overcomes the resistance. They also found that amiloride, a drug that blocks the same sodium channel in the kidney but without touching the MR, was nearly as effective, lending support to the idea that sodium retention is the core problem.11PubMed Central. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Diabetic Kidney Disease
The approval of finerenone for diabetic kidney disease marked a major expansion of what MRAs are used for. In two large trials enrolling patients with type 2 diabetes and albuminuria (protein leaking into the urine, a sign of kidney damage), finerenone slowed the progression of kidney disease and reduced cardiovascular events compared with placebo, on top of standard care that already included drugs blocking the renin-angiotensin system.
A mediation analysis of those trials found that reducing albuminuria accounted for about 84% of finerenone’s benefit on kidney outcomes and about 37% of its cardiovascular benefit. Among patients taking finerenone, over half achieved a 30% or greater reduction in urine albumin, compared with roughly a quarter on placebo.12PubMed. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis These findings suggest that while lowering albuminuria is a key mechanism, finerenone also protects the cardiovascular system through pathways that go beyond kidney-specific effects, likely by reducing inflammation and fibrosis in the heart and vasculature.
Cirrhosis and Ascites
When the liver becomes severely scarred, portal hypertension drives fluid into the abdominal cavity, producing ascites. The hormonal environment in advanced cirrhosis involves high levels of aldosterone because the damaged liver fails to clear it efficiently, and the body’s volume-sensing systems perceive low effective blood volume and ramp up aldosterone production even further. Spironolactone is the first-line diuretic for this condition, often combined with a loop diuretic like furosemide when spironolactone alone is not enough to mobilize the fluid.13PubMed Central. Diagnosis and therapy of ascites in liver cirrhosis This use predates the heart failure trials by decades and remains one of the most common reasons spironolactone is prescribed worldwide.
Anti-Androgenic Effects and Dermatological Uses
Spironolactone’s tendency to block androgen receptors is a side effect in cardiac patients but a feature in dermatology. In women, it is widely prescribed off-label for hormonal acne, female-pattern hair loss, and excess body hair. It is inexpensive, has a long track record, and can reduce the need for systemic antibiotics or more aggressive drugs for acne.14PubMed. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism
The evidence base, while supportive in clinical practice, is not as clean as you might expect. A systematic review of randomized trials in adult women with acne found that most studies were at high risk of bias and the quality of evidence was low. Only one crossover trial showed clear statistical superiority of a high daily dose over placebo for inflamed lesions.15PubMed Central. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review Dermatologists continue prescribing it because decades of clinical experience and case-series data align with the pharmacology, even if the trial evidence has not caught up to the strength clinicians would like. Spironolactone is not used for acne in men because its anti-androgenic effects would cause feminizing side effects.
Side Effects Worth Knowing About
The side effect that most concerns clinicians is hyperkalemia, a rise in blood potassium. Because MRAs prevent potassium from being excreted in the kidneys, anyone on these drugs needs periodic blood tests. The risk is highest in people who already have kidney impairment or who are taking other drugs that raise potassium, such as ACE inhibitors and angiotensin receptor blockers (which are often prescribed alongside MRAs for heart failure). In the finerenone kidney-disease trials, the protocol called for suspending the drug whenever potassium rose above 5.5 mmol/L, rechecking every 72 hours, and resuming once levels dropped to 5.0 or below. Permanent discontinuation was reserved for recurrent hyperkalemia.16Nephrology Dialysis Transplantation. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? This careful dose-adjustment strategy keeps the overall rate of serious hyperkalemia low in trial settings, though real-world monitoring may be less meticulous.
Spironolactone’s off-target hormonal effects are the other major concern. In men, breast tenderness and breast enlargement (gynecomastia) are common enough at higher doses to limit use. Women may experience menstrual irregularities or breast tenderness. Eplerenone largely avoids these problems because it is far more selective for the mineralocorticoid receptor and has minimal affinity for androgen and progesterone receptors.3PubMed. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone Non-steroidal MRAs like finerenone also sidestep the sex-hormone issue entirely.
Beyond Fluid Balance: Fighting Fibrosis
One of the more important developments in MRA research has been the recognition that much of their benefit comes from blocking the scarring and stiffening that aldosterone causes in the heart, kidneys, and blood vessels, independent of blood pressure changes. In animal models, eplerenone improved how well the heart relaxed and filled in hypertensive rats, and this improvement was not simply a consequence of lower blood pressure.17PubMed Central. Mineralocorticoid receptor antagonists in cardiovascular translational biology Finerenone, in a mouse model of heart disease, prevented chamber dilation, reduced the expression of several proteins that drive fibrosis, and cut down the amount of scar tissue in both the left ventricle and left atrium.18PubMed. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
This anti-fibrotic dimension helps explain why MRAs benefit patients with diabetic kidney disease (where fibrosis drives progressive loss of kidney function) and why finerenone, with its balanced tissue distribution and distinct gene-expression profile, appears to have particular anti-fibrotic potency. It also opens the door to potential future applications in conditions where organ fibrosis is central, such as liver disease or pulmonary fibrosis, though clinical evidence in those areas is still early.
Combining MRAs with Newer Drugs
In diabetic kidney and heart disease, the modern treatment landscape involves layering drugs that work through complementary pathways. An analysis modeling the lifetime benefits of combining three drug classes, SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs, in patients with type 2 diabetes and albuminuria estimated that the combination reduced major cardiovascular events by about 35% compared with conventional care. Over three years, the estimated absolute risk reduction was about 4.4%, meaning roughly 23 patients would need to be treated to prevent one major cardiovascular event.19PubMed. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
In heart failure with preserved or mildly reduced ejection fraction specifically, data from the finerenone trials suggest that adding finerenone to an SGLT2 inhibitor may provide additive cardiovascular protection, not just duplication of the same effect.20PubMed Central. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure The practical implication is that clinicians increasingly think of MRAs not as standalone drugs but as one pillar of a multi-drug approach that addresses inflammation, fibrosis, sodium handling, and metabolic dysfunction simultaneously.
A Surprising Connection to Sleep Apnea
One of the more unexpected findings in MRA research involves obstructive sleep apnea. In patients with resistant hypertension, which overlaps substantially with sleep apnea, spironolactone treatment cut the severity of apnea events by roughly half. The apnea-hypopnea index, the standard measure of sleep apnea severity, dropped from about 40 events per hour to about 22 in one study.21PubMed Central. Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report A separate study confirmed that spironolactone reduced both apnea severity and blood pressure over 12 weeks in patients with resistant hypertension and moderate-to-severe sleep apnea.22Clinical and Experimental Hypertension. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea
The proposed mechanism is that aldosterone-driven fluid retention causes swelling of the soft tissues in the throat. When you lie down at night, gravity redistributes that retained fluid toward the head and neck, increasing upper-airway resistance and making the airway more likely to collapse. By blocking aldosterone and promoting fluid loss, spironolactone reduces that pharyngeal swelling. This remains a small-study finding and has not been tested in large randomized trials, but it illustrates how the effects of MR activation extend well beyond blood pressure numbers.
Mineralocorticoid Receptors in the Brain and Blood Vessels
A small number of mineralocorticoid receptors in the brain help regulate blood pressure, fluid balance, sodium appetite, and the sympathetic nervous system’s drive to the rest of the body. Aldosterone can bind brain MRs despite circulating at concentrations far lower than cortisol and corticosterone, which have similar affinity for the receptor.23Trends in Endocrinology & Metabolism. Mineralocorticoid Receptor Antagonists: How They Work & Uses This means that even at low circulating levels, aldosterone can amplify sympathetic tone and elevate blood pressure through central nervous system pathways. Brain MRs also play a role in learning and memory, and inappropriate activation has been linked to cardiovascular and renal disease.24PubMed Central. Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis
In blood vessel walls, both smooth muscle cells and the cells lining the interior of vessels express functional mineralocorticoid receptors. Activation promotes stiffness, inflammation, and remodeling of the vessel wall. Whether MRA drugs cross the blood-brain barrier effectively enough to block central MR at standard clinical doses is still being studied, but the vascular effects are well established and contribute to the blood-pressure-independent benefits seen in clinical trials.
Why Response Varies from Person to Person
Not everyone responds the same way to an MRA, and genetics is part of the explanation. A study of Egyptian heart failure patients found that two genetic variants, one in the gene encoding angiotensinogen and one in the gene for an enzyme involved in aldosterone synthesis, together with baseline potassium levels, explained about 71% of the variability in how much heart function improved with spironolactone therapy. The same factors accounted for about 63% of the variability in potassium increase and roughly 39% of differences in quality-of-life improvement.25PubMed Central. Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure This is a single-population study, so the specific percentages should be interpreted cautiously, but the broader point is solid: individual variation in the hormonal axis that MRAs target strongly influences how much benefit a given patient gets.
Beyond genetics, kidney function at baseline matters enormously. Someone with already-impaired kidneys will retain more potassium on an MRA, potentially making the drug too dangerous to continue. Age, dietary potassium intake, and what other medications a person takes all shift the risk-benefit balance. This is why MRA prescribing typically involves frequent lab monitoring in the first few weeks, with adjustments tailored to each patient’s response.
Topical Formulations and Wound Healing
Most people encounter MRAs as oral pills, but researchers are developing topical formulations aimed at delivering spironolactone directly to the skin. The motivation is to exploit the drug’s anti-androgenic properties for conditions like acne and hair loss while avoiding the systemic hormonal side effects that limit oral dosing, especially in men. Spironolactone’s poor solubility has been a barrier, spurring development of nanoparticle-based carriers including lipid nanoparticles, polymeric nanoparticles, and nanofibers that improve drug penetration into the skin.26PubMed Central. A Systematic Review of Spironolactone Nano-Formulations for Topical Treatment of Skin Hyperandrogenic Disorders and Chronic Wounds
Interestingly, the mineralocorticoid receptor itself is concentrated in the pilosebaceous unit, the structure that houses the hair follicle and sebaceous gland. Polymeric micelle carriers can deliver spironolactone preferentially to these appendageal structures, depositing pharmacologically meaningful amounts into the upper layers of the skin.27PubMed. Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing Beyond androgen-driven skin conditions, there is interest in using topical MRAs to counteract the delayed wound healing caused by glucocorticoid creams, since glucocorticoids can activate the MR in skin and slow tissue repair. These formulations are still in preclinical and early clinical stages, but they point toward a future where MRAs have a role well beyond cardiology and nephrology.
An Evolutionary Quirk
The mineralocorticoid receptor is ancient. Its ancestor, a generic corticoid receptor, exists in jawless fish like lampreys and hagfish. A distinct MR first appeared in cartilaginous fish like sharks and rays, where it responds strongly to multiple steroid hormones because these species do not make aldosterone. In fact, aldosterone as a hormone appears only in terrestrial vertebrates, and its emergence coincided with a molecular switch that made spironolactone and progesterone act as antagonists at the MR in land animals. In zebrafish, both compounds actually activate the receptor rather than blocking it.28PubMed Central. Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist The move to land required tighter control over sodium and water balance in a dehydrating environment, and aldosterone evolved as a dedicated mineralocorticoid for that purpose. Without that evolutionary pressure, the very drugs we use to block the receptor today would have the opposite effect.29PubMed. Evolution of the mineralocorticoid receptor: sequence, structure and function